within Pharmacolibrary.Drugs.ATC.J;

model J05AE03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 0.000245,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0882,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.010666666666666666,
    Tlag           = 10.001999999999999,            
    Vdp             = 0.5438999999999999,
    k12             = 61.5,
    k21             = 61.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AE03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ritonavir is an antiretroviral medication belonging to the class of protease inhibitors. It is primarily used as a pharmacokinetic enhancer or booster of other protease inhibitors or direct-acting antivirals in the treatment of HIV/AIDS. Ritonavir is approved and widely used today in combination therapies as part of highly active antiretroviral therapy (HAART), as well as in combination with other antivirals for COVID-19.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult volunteers following single oral dose administration.</p><h4>References</h4><ol><li><p>Saravolatz, LD, et al., &amp; Sharma, M (2023). Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 76(1) 165–171. DOI:<a href=&quot;https://doi.org/10.1093/cid/ciac180&quot;>10.1093/cid/ciac180</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35245942/&quot;>https://pubmed.ncbi.nlm.nih.gov/35245942</a></p></li><li><p>Lennernäs, H (2003). Clinical pharmacokinetics of atorvastatin. <i>Clinical pharmacokinetics</i> 42(13) 1141–1160. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200342130-00005&quot;>10.2165/00003088-200342130-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/14531725/&quot;>https://pubmed.ncbi.nlm.nih.gov/14531725</a></p></li><li><p>Hammond, J, et al., &amp; Rusnak, JM (2022). Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. <i>The New England journal of medicine</i> 386(15) 1397–1408. DOI:<a href=&quot;https://doi.org/10.1056/NEJMoa2118542&quot;>10.1056/NEJMoa2118542</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35172054/&quot;>https://pubmed.ncbi.nlm.nih.gov/35172054</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AE03;
